Modified immune cells for recurrent brain cancer
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a new treatment using your own immune cells that are genetically modified to find and attack brain tumor cells. It is for people with a type of brain cancer that has come back after standard therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old.
- Your tumor must be a type of brain cancer called glioblastoma or a grade 3 or 4 IDH-mutant astrocytoma that has come back after standard treatment.
- Your tumor must have a specific protein called IL13Rα2 (this is checked by a lab test).
- You need to be well enough to do daily activities (Karnofsky score of 70 or more).
- You must have adequate blood counts and organ function (kidney, liver, lungs) and be free of HIV, hepatitis B, and C.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests genetically engineered immune cells (CAR T cells) injected directly into the brain to treat recurring or worsening high-grade gliomas. The cells are designed to recognize and attack tumor cells that have specific markers (EGFR and IL13Rα2).
This trial tests a new treatment using engineered immune cells (CAR-NK cells) that target two markers found on glioblastoma tumors. The treatment is given directly into the brain to fight tumors that have come back after standard therapy.
This trial tests a new type of immune cell therapy called CAR-NK cells to treat glioblastoma or high-grade glioma that has come back or gotten worse after standard treatment. The cells are engineered to recognize and attack tumor cells in the brain.
This early-phase trial studies a personalized immune-cell treatment (CAR-T) for glioblastoma that has come back. It aims to shrink or control the regrowing brain tumor by using your own immune cells after processing them in a lab.
This trial tests engineered immune cells (called NK cells) that are designed to fight glioblastoma, a deadly brain cancer. The cells are injected directly into the tumor and may help patients whose cancer has come back after standard treatment.
This Phase 1 study tests an “allogenic” stem cell product made from donated fat tissue to treat recurrent glioblastoma or certain recurrent astrocytoma. It gives the treatment around the time of a repeat brain surgery, and focuses on safety while also studying why it might help.
Hear when a new Recurrent Astrocytoma, IDH-Mutant, Grade 4 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.